Edwards Lifesciences Corporation (EW)
$
81.34
+0.11 (0.14%)
Key metrics
Financial statements
Free cash flow per share
1.0356
Market cap
47.8 Billion
Price to sales ratio
8.4000
Debt to equity
0.0666
Current ratio
4.6823
Income quality
0.1919
Average inventory
1.1 Billion
ROE
0.4125
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Edwards Lifesciences Corporation specializes in providing innovative products and technologies aimed at treating structural heart disease, as well as critical care and surgical monitoring solutions in various global markets including the United States, Europe, and Japan. The company recorded an operating income of $1,378,700,000.00 reflecting its earnings from core operations. It reported a substantial revenue of $5,439,500,000.00 showcasing its strong market presence in the industry. The company offers transcatheter heart valve replacement products, allowing for minimally invasive heart valve replacements, along with transcatheter valve repair and replacement products targeting mitral and tricuspid valve diseases. Additionally, the company provides the PASCAL and Cardioband transcatheter valve repair systems, which facilitate minimally-invasive therapies. In terms of surgical structural heart solutions, it offers solutions like the aortic surgical valve under the INSPIRIS name and KONECT RESILIA, a pre-assembled aortic tissue valved conduit designed for patients needing valve and root replacements alongside the ascending aorta. The HARPOON Beating Heart Mitral Valve Repair System is also available for patients suffering from degenerative mitral regurgitation. Furthermore, Edwards Lifesciences delivers critical care solutions including advanced hemodynamic monitoring systems that assess heart function and fluid status in surgical and intensive care settings, as well as the Acumen Hypotension Prediction Index software, which provides timely alerts to clinicians regarding dangerously low blood pressure. The company reported an income before tax of $1,548,100,000.00 showcasing its pre-tax profitability, and the operating income ratio stands at $0.25 indicating the company's operational profitability margin. In the financial market, the stock is reasonably priced at $78.28 appealing to a broad range of investors and reflecting the company’s robust standing. The stock has a high average trading volume of 4,126,701.00 indicating strong liquidity which can attract both new and seasoned investors. With a mid-range market capitalization of $47,754,714,000.00 the company continues to be a steady performer within its sector. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape while driving innovation and growth in the Healthcare sector.
Is Edwards Lifesciences Corporation (EW) a good investment?
Investing in Edwards Lifesciences Corporation (EW) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bullish outlook. Always conduct your own research before investing.
What is Edwards Lifesciences Corporation (EW)'s stock forecast?
Analysts predict Edwards Lifesciences Corporation stock to fluctuate between $64.01 (low) and $83 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Edwards Lifesciences Corporation's market capitalization?
As of 2025-08-29, Edwards Lifesciences Corporation's market cap is $47,754,714,000, based on 587,100,000 outstanding shares.
How does Edwards Lifesciences Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Edwards Lifesciences Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Edwards Lifesciences Corporation (EW) stock?
To buy Edwards Lifesciences Corporation (EW) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for EW. Place an order (Market, Limit, etc.).
What is the best time to invest in Edwards Lifesciences Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Edwards Lifesciences Corporation stock ever split?
Edwards Lifesciences Corporation's last stock split was 3:1 on 2020-06-01.
How did Edwards Lifesciences Corporation perform in the last earnings report?
Revenue: $5,439,500,000 | EPS: $6.98 | Growth: 202.16%.
Where can I find Edwards Lifesciences Corporation's investor relations reports?
Visit https://www.edwards.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Edwards Lifesciences Corporation?
You can explore historical data from here
What is the all-time high and low for Edwards Lifesciences Corporation stock?
All-time high: $131.73 (2021-12-30) | All-time low: $58.93 (2024-07-25).
What are the key trends affecting Edwards Lifesciences Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
MADRID--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for valvular heart disease, which establish a simplified care pathway for all severe aortic stenosis (AS) patients, regardless of symptoms. The guidelines enable a proactive approach to disease management and underscore that intervention should be considered for asymptomatic patients, regardless of heart function, which is a meaningful step forward from the prior practice of “watchful waiting.” Th.
businesswire.com
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $500 million of Edwards' common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025. Under the terms of this ASR, Edwards will receive an initial delivery of approximately 5 million shares and the remainder at the maturity of the ASR. The final number of shares to be repurchased will be ba.
globenewswire.com
Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Edwards (EW) To Contact Him Directly To Discuss Their Options
globenewswire.com
IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition by Edwards Lifesciences.
benzinga.com
Edwards Lifesciences EW has just entered Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly chart. While the stock's setup doesn't necessarily point to a bearish outlook, the structure suggests that sluggish, range-bound price action could dominate through early 2027.
benzinga.com
Edwards Lifesciences' EW stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies.
zacks.com
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
seekingalpha.com
Edwards Lifesciences Corporation (NYSE:EW ) Q2 2025 Earnings Conference Call July 24, 2025 5:00 PM ET Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Director Scott Ullem - Corporate VP & CFO Larry Wood - Corporate VP and Group President of TAVR & Surgical Structural Heart Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Securities, LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Matthew Taylor - Jefferies LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Christopher Pasquale - Nephron Research LLC Operator Greetings, and welcome to the Edwards Lifesciences Second Quarter 2025 Results Conference Call. [Operator Instructions].
zacks.com
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
reuters.com
Edwards Lifesciences raised its 2025 sales forecast on Thursday, citing strong demand for its artificial heart valves and other medical devices, after posting better-than-expected results for the second quarter.
See all news
